Figures
Abstract
Background & Aims
The cellular immunity has a profound impact on the status of hepatitis C virus (HCV) infection. However, the response of cellular immunity on the virological response in patients with antiviral treatment remains largely unclear. We aimed to clarify the response of peripheral T cells and monocytes in chronic hepatitis C patients with antiviral treatment.
Methods
Patients with chronic hepatitis C were treated either with interferon alpha-2b plus ribavirin (n = 37) or with pegylated interferon alpha-2a plus ribavirin (n = 33) for up to 24 weeks. Frequencies of peripheral regulatory T-cells (Tregs), programmed death-1 (PD-1) expressing CD4+ T-cells or CD8+ T-cells and toll-like receptor (TLR) 3 expressing CD14+ monocytes were evaluated by flow cytometry in patients at baseline, 12 and 24 weeks following treatment and in 20 healthy controls.
Results
Frequencies of Tregs, PD-1 and TLR3 expressing cells were higher in patients than those in control subjects (P<0.05). Patients with complete early virological response (cEVR) showed lower Tregs, PD-1 expressing CD4+ or CD8+ T-cells than those without cEVR at 12 weeks (P<0.05). Patients with low TLR3 expressing CD14+ monocytes at baseline had a high rate of cEVR (P<0.05).
Citation: Su S-s, He H, Kong L-b, Zhang Y-g, Zhao S-x, Wang R-q, et al. (2014) Regulatory Phenotype, PD-1 and TLR3 Expression in T Cells and Monocytes from HCV Patients Undergoing Antiviral Therapy: A Randomized Clinical Trial. PLoS ONE 9(4): e93620. https://doi.org/10.1371/journal.pone.0093620
Editor: T. Mark Doherty, Glaxo Smith Kline, Denmark
Received: September 2, 2013; Accepted: March 6, 2014; Published: April 7, 2014
Copyright: © 2014 Su et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by the Key Program for Science and Technology Development of Hebei Province named Study on Prevention and Control of Viral Hepatitis (10276102D). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Hepatitis C virus (HCV) infection is a growing public health problem, with roughly 3% of the population infected worldwide [1], [2]. Interferon alpha (IFNα) in combination with ribavirin (RBV) remains a gold standard treatment for chronic HCV infection. However, approximately one-half of chronic hepatitis C genotype 1 patients fail to achieve viral clearance [3]. Thus, it is important to identify the factors that may be valuable in improving antiviral strategy and treatment response.
Both innate and adaptive immunity have a profound impact on status of HCV infection. Impairment of host immunity, especially HCV-specific cellular immune response, may lead to chronic infection [4], [5]. Regulatory T-cells (Tregs) have been shown to be increased in the peripheral blood of patients with chronic HCV infection and can suppress the proliferation of HCV-specific cytotoxic T lymphocytes, which may affect the antiviral treatment response [6]–[8]. Programmed cell death-1 (PD-1), expressing in activated T cells, B cells and monocytes, plays an essential role in regulation of adaptive immune responses [9]. Virus-specific CD8+ T cell response generated during acute HCV infection can be gradually exhausted in settings of persistent virus infections by the high expression of PD-1 [10]–[13]. Studies have shown that toll-like receptors (TLRs) can detect the presence of HCV infection through recognition of viral pathogen-associated molecular patterns (PAMPs) and control activation of the adaptive immune responses by inducing dendritic cell maturation [14], [15]. In human monocytes, TLR3 is localized in intracellular endosomal compartments and the agonist of TLR3 represents an attractive target for pursuing the HCV clearance [16]. However, up to now, the effects of Tregs, PD-1 expressing CD4+ T-cells or CD8+ T-cells and TLR3 expressing CD14+ monocytes on virological response in patients treated with IFNα plus RBV remains poorly understood. In this study, we aimed to clarify the role of Tregs, PD-1 and TLR3 in treatment response by assessing the baseline levels and dynamic changes of these immune mediators in patients receiving the combined antiviral treatment.
Patients and Methods
Ethics Statement
The protocol for this trial and supporting CONSORT checklist are available as supporting information; see Checklist S1 and Protocol S1. This was a randomized parallel-group study conducted in Shijiazhuang, China. The study protocol conformed to the guidelines of the 1975 Declaration of Helsinki and was approved by the ethics committees of Third Hospital of Hebei Medical University, Shijiazhuang, China, and all patients provided written informed consent. The registration number was ChiCTR-TNRC-10001090.
Subjects
A total of 70 patients chronically infected with HCV were recruited from Third Hospital of Hebei Medical University, the Fifth Hospital of Shijiazhuang City and Bethune International Peace Hospital (Shijiazhuang, China). The complete date range for patient recruitment and follow-up was from January 2011 to October 2012. HCV infection was diagnosed on the basis of the serum positive antibodies to HCV and the presence of HCV RNA in the plasma. Eligible patients were ≥18 years of age. Subjects meeting with the following criteria were excluded: presence of decompensated cirrhosis, co-infection with human immunodeficiency virus (HIV), hepatitis A, B or D virus, other causes of chronic liver disease or co-morbidities precluding interferon therapy. Twenty age and gender matched healthy subjects were used as controls. Peripheral blood was collected from all of the healthy controls and chronic hepatitis C patients at baseline, 12 and 24 weeks after treatment.
HCV Antibodies Tests
The serum antibodies to HCV were detected by enzyme linked immunosorbent assay (ELISA) with a commercial detection kit (Livzon diagnostics INC, Zhuhai, China).
Quantitative Detection of HCV RNA
HCV RNA load was determined using qualitative reverse transcriptase polymerase chain reaction (RT-PCR) assay (Cobas Taqman HCV Test, Roche Diagnostics, Indianapolis, IN) and the low limit quantification was 15 IU/ml.
Biochemical Assays
Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were detected by an Olympus AU5400 automatic chemical analyzer.
HCV Genotyping
The HCV genotypes were identified using the HCV genotyping oligochip (Tianjin Third Central Hospital, China) [17].
Treatments and Assessments of Virological Responses
Participants were randomly assigned following simple randomization procedures. Eligible subjects were randomly divided into 2 groups: IFNα-2b plus RBV (IFNα-2b/RBV) group (n = 37), patients underwent therapy of recombinant IFNα-2b (300 million units for body weight<60 kg and 500 million units for body weight≥60 kg, on alternate days) (Beijing Kawin Technology Share-holding Co, Ltd. China) plus weight-based RBV (13–15 mg/kg⋅d) (Zhejiang Chengyi pharmaceuticals Co, Ltd. China); PegIFNα-2a plus RBV (PegIFNα-2a/RBV) group (n = 33), patients received PegIFNα-2a (135 μg/week for body weight<60 kg and 180 μg/week for body weight≥60 kg, subcutaneously) (Pegasys, Roche, Basel, Switzerland) plus weight-based RBV (13–15 mg/kg⋅d) (Fig. 1). Responses to the treatment were assessed by detecting plasma HCV RNA levels at baseline, 12 and 24 weeks after the treatment. Standard definitions of responses were used to evaluate the therapeutic effect [18]. Complete early virological response (cEVR) was defined as undetectable plasma HCV RNA at 12 weeks after treatment. Full details of the trial protocol can be found in the Supplementary Appendix, available with the full text of this article at www.chictr.org/cn/.
Flow Cytometry Assay for Tregs, PD-1 Expressing T-cells and TLR3 Expressing CD14+ Monocytes
Fluorescent dye conjugated antibodies consisted of cell surface monoclonal antibodies CD4-fluorescein isothiocyanate (FITC), CD8-peridinin-chlorophyll-protein complex (PerCP)-Cy5.5, PD-1-phycoerythrin (PE), CD25-PE and CD14-FITC (all from BD Biosciences, San Jose, CA), and intracellular monoclonal antibodies FoxP3-Alexa Flour 647 (BD Biosciences) and TLR3-PE (from eBioscience, San Diego, CA). All appropriate isotype controls were obtained from BD Biosciences. Intracellular staining of FoxP3 was performed according to the manufacturer’s staining kit (BD Biosciences) instructions. Cell surface antigens to identify the PD-1 expression on CD4+ or CD8+ T-cells were detected with CD4-FITC, CD8-PerCP-Cy5.5 and PD-1-PE. To detect intracellular TLR3 expression in monocytes, cells were stained with surface antibodies CD14-FITC, fixed, permeabilized using FACS™ permeabilizing solution 2 (BD Biosciences) and incubated with TLR3-PE.
At least 100,000 cells were acquired on FACS CantoII (Becton Dickinson, San Jose, CA) and analyzed using Cellquest software. For data analyses, an initial lymphocyte gate was set based on side scatter (SSC)/forward scatter (FSC) and additional gates introduced as required. Results were present as the percentage of positively stained cells within the gated population.
Statistics Analysis
The statistical power calculation was performed based on predictive significance of cEVR to sustained virological response (SVR) achievement. The target sample size gave 95% power at the 5% significance level to detect a difference of 58% in SVR rates (82.2% vs 24.2%) between the cEVR and non-cEVE patients according to the outcome of our completed clinical trial. Categorical data were expressed as numbers or proportions of subjects with the specific features. The chi-square test was used to compare categorical data. Continuous variables not normally distributed were summarized as medians and ranges, and Nonparametric Mann-Whitney U test was used to compare the differences between two groups. Kruskal-Wallis H test was used for comparison of differences between three groups and further comparisons between any two groups within these multiple groups were conducted using Nemenyi method. A mixed-effects model analysis of variance was applied to evaluate the time and group effects as well as the time by group interaction. If the overall P-value was significant, we used a step-down test based on the Bonferroni correction method to determine pairwise differences. Correlations between the variables were calculated using Spearman rank order correlations. Multivariate logistic regression analysis was performed to identify independent predictors of cEVR. All P-values were two-tailed, and were considered significant when lower than 0.05. Data were analyzed using SPSS 16.0 software package (v. 16.0; SPSS Inc., Chicago, IL).
Results
Patient Characteristics
At baseline, there were no significant differences between IFNα-2b/RBV and PegIFNα-2a/RBV treatment groups for the demographic and clinical characteristics, including gender, age, body mass index, serum ALT, AST, HCV RNA levels, percentages of different contaminated ways and HCV genotypes (Table 1). The age and gender between chronic hepatitis C patients and healthy controls were also no significant difference (data not shown).
Among 70 patients, 61 (87.1%, 61/70) of them were infected with HCV genotype 1b and 6 (8.6%, 6/70) patients were infected with HCV genotype 2a. The HCV genotype data were missing in 3 (4.3%, 3/70) patients.
Treatment Responses
As 4 cases who didn’t provide requested information at 12 weeks after treatment were missing, 66 subjects were included in the efficacy analysis for cEVR assessment (34 patients treated with IFNα-2b/RBV and 32 cases with PegIFNα-2a/RBV). Among 34 patients treated with IFNα-2b/RBV, 25 (73.5%, 25/34) achieved cEVR, and 25 (78.1%, 25/32) underwent PegIFNα-2a/RBV treatment achieved cEVR. There was no significant difference in the cEVR incidences between the two groups (P = 0.663).
We evaluated the potential relationship between HCV genotypes and early response patterns (cEVR or non-cEVR). Among 66 subjects included in the efficacy analysis for cEVR assessment (60 patients infected with HCV genotype 1b and 6 cases with HCV genotype 2a), 45 (75.0%, 45/60) patients with HCV genotype 1b infection achieved cEVR, while 5 (83.3%, 5/6) patients infected with HCV genotype 2a achieved cEVR.
Tregs and Virological Response
The effect of different types of interferon combined with RBV on peripheral CD4+CD25+FoxP3+ Tregs proportion in CD4+ T-cells was assessed. The Tregs frequency was higher in chronic hepatitis C patients than that in the controls (P = 0.031) (Fig. 2), which was significantly decreased at 12 weeks after treatment with IFNα-2b/RBV (P = 0.015) (Fig. 3A) or PegIFNα-2a/RBV (P = 0.034) (Fig. 3B). No further change was observed at 24 weeks compared with 12 weeks following treatment. With respect to the Tregs levels, no significant difference was observed between IFNα-2b/RBV and PegIFNα-2a/RBV groups in any time point (P>0.05). A representative flow cytometry dot plot of Tregs proportion in CD4+ T-cells was shown in Fig. 4A and 4B.
Boxes represent the interquartile range and horizontal lines inside each box represent the median. The vertical lines from the ends of each box encompass the extreme data points. Proportions of Tregs, PD-1 expressing CD4+ T-cells or CD8+ T-cells and TLR3 expressing CD14+ monocytes were measured by flow cytometry and data were presented by percentage. P-values were determined by Mann-Whitney test. *P<0.05, **P<0.01, ***P<0.001.
Boxes represent the interquartile range and horizontal lines inside each box represent the median. The vertical lines from the ends of each box encompass the extreme data points. Proportions of Tregs, PD-1 expressing CD4+ T-cells or CD8+ T-cells and TLR3 expressing CD14+ monocytes were measured by flow cytometry and data were presented by percentage. P-values were determined by Kruskal-Wallis H test and Nemenyi test. *P<0.05, **P<0.01, ***P<0.001.
(A) CD4+ lymphocytes were gated by positive staining of CD4 and side scatter (SSC). (B) Dot plots illustrating CD4+CD25+FoxP3+ Tregs in CD4+ cells. Cells were stained with monoclonal antibodies to CD4, CD25 and FoxP3. The lymphocyte subpopulation was selected on the basis of forward scatter (FSC) and SSC from peripheral blood cells. The percentage of positive cells is indicated in the upper right region.
As compared with the baselines, the Tregs frequency was significantly decreased at 12, 24 weeks in cEVR patients (P<0.001) and at 24 weeks in non-cEVR cases (P = 0.001 and P = 0.015, respectively) after treatment with IFNα-2b/RBV or PegIFNα-2a/RBV (Fig. 5A and 5B). Futhermore, Tregs frequency was significantly lower in cEVR patients than that in non-cEVR cases after 12 weeks of medication (P<0.001 and P = 0.015, respectively) (Fig. 5C and 5D), whereas no significant difference in the proportion was found at baseline and 24 weeks after therapy (Fig. 5C and 5D).
Boxes represent the interquartile range and horizontal lines inside each box represent the median. The vertical lines from the ends of each box encompass the extreme data points. Proportions of Tregs, PD-1 expressing CD4+ T-cells or CD8+ T-cells and TLR3 expressing CD14+ monocytes were measured by flow cytometry and data were presented by percentage. P-values were determined by mixed model and Bonferroni correction method. *P<0.0167.
PD-1 Expressing CD4+ Or CD8+ T-cells and Virological Response
PD-1 expression on T-cell subsets was determined by the percentage of PD-1 positive cells. The PD-1 expressing CD4+ T-cells (P = 0.012) or CD8+ T-cells (P = 0.004) were significantly higher in chronic hepatitis C patients than those in healthy controls at baseline (Fig. 2). Compared with its baseline level, PD-1 expressing CD8+ T-cells was decreased after 12 weeks of therapy in patients received IFNα-2b/RBV (P = 0.035) or PegIFNα-2a/RBV (P = 0.015), and further reduced at 24 weeks after treatment compared with its 12 weeks level (P = 0.034 and P = 0.029, respectively) (Fig. 3A and 3B). However, the PD-1 expressing CD4+ T-cells did not show significant change after antiviral treatment. In addition, there was no significant difference of the PD-1 expressing CD4+ T-cells or CD8+ T-cells between IFNα-2b/RBV and PegIFNα-2a/RBV groups in any parallel time point (P>0.05). A representative flow cytometry dot plot of PD-1 expressing CD4+ or CD8+ T-cells was shown in Fig. 6A and 6B.
(A) Dot plots illustrating PD-1 expressing CD4+ cells and (B) CD8+ cells. Cells were stained with monoclonal antibodies to CD4, CD8 and PD-1. The lymphocyte subpopulation was selected on the basis of forward scatter (FSC) and side scatter (SSC) from peripheral blood cells. CD4+ or CD8+ lymphocytes were gated by positive staining of CD4 or CD8 and SSC. The percentage of positive cells is indicated in the upper right region.
By analyzing the relationship between PD-1 level and virological response, compared with the baseline levels, PD-1 expressing CD4+ T-cells were markedly decreased after 12 weeks of therapy with IFNα-2b/RBV (P = 0.004) or PegIFNα-2a/RBV (P<0.001) in cEVR patients, but it did not show significant change in non-cEVR cases (Fig. 5A and 5B). As respect to PD-1 expressing CD8+ T-cells, we found that it’s frequency was significantly decreased at 12, 24 weeks in cEVR patients (P<0.001) and at 24 weeks in non-cEVR cases (P = 0.009 and P = 0.006, respectively) after treatment with IFNα-2b/RBV or PegIFNα-2a/RBV (Fig. 5A and 5B). Compared with non-cEVR patients, frequencies of PD-1 expressing CD4+ (P = 0.005 and P = 0.002, respectively) in two treatment groups and PD-1 expressing CD8+ T-cells (P = 0.001) in IFNα-2b/RBV treated group were significantly lower in patients who achieved cEVR after 12 weeks of therapy (Fig. 5C and 5D), though no differences were seen at baseline and 24 weeks after treatment (Fig. 5C and 5D).
TLR3 Expressing CD14+ Monocytes and Virological Response
TLR3 expressing CD14+ monocytes, determined by the percentage of TLR3 positive cells, were higher in chronic hepatitis C patients than those in healthy controls (P<0.001) (Fig. 2), and further increased after 12 weeks of treatment (P = 0.033 and P = 0.018, respectively), but returned to baseline level at 24 weeks in the two treatment groups (Fig. 3A and 3B). No significant difference was presented in TLR3 expressing CD14+ monocytes between IFNα-2b/RBV and PegIFNα-2a/RBV groups in any parallel time point (P>0.05). A representative flow cytometry dot plot of TLR3 expressing CD14+ monocytes was shown in Fig. 7A and 7B.
(A) CD14+ monocytes were gated by positive staining of CD14 and side scatter (SSC). (B) Dot plots illustrating TLR3 expressing CD14+ cells. Cells were stained with monoclonal antibodies to CD14 and TLR3. The percentage of positive cells is indicated in the upper right region.
TLR3 expressing CD14+ monocytes were significantly increased after 12 weeks of treatment (P<0.001), and restored close to the baseline levels at 24 weeks in cEVR patients of the two treatment groups, but this changes were not significant in non-cEVR cases (Fig. 5A and 5B). Notably, the baseline TLR3 expressing CD14+ monocytes were significantly lower in patients achieved cEVR than those with non-cEVR (P = 0.009 and P = 0.011, respectively) (Fig. 5C and 5D), whereas there was no relationship between TLR3 expressing CD14+ monocytes and virological response at 12 and 24 weeks after treatment in the two groups (Fig. 5C and 5D).
Predict Factors of Treatment Response
Variables that may be related to treatment response were assessed by multivariate logistic regression analysis, including baseline laboratory parameters, consisting of Tregs, PD-1expressing CD4+ T-cells or CD8+ T-cells, TLR3 expressing CD14+ monocytes, serum viral load, ALT and AST, as well as the use of interferon types. It was found that low proportion of baseline TLR3 expressing CD14+ monocytes was a single predictor of cEVR in chronic hepatitis C patients with antiviral treatment [odds ratio (OR) = 2.11, 95% confidence intervals (CI) (1.15–3.88), P = 0.023].
Lack of Association of Tregs, PD-1 and TLR3 with HCV Genotype, Viral Load, ALT and AST
Relationships of the baseline levels and the dynamic changes during treatment of Tregs, PD-1 expressing CD4+ T-cells or CD8+ T-cells and TLR3 expressing CD14+ monocytes with HCV genotypes were analyzed. No difference was found between HCV genotype 1b and 2a infected patients at each time point (data not shown). Moreover, there was no correlation of Tregs, PD-1 expressing CD4+ T-cells or CD8+ T-cells and TLR3 expressing CD14+ monocytes with baseline HCV load, ALT and AST levels as well (data not shown).
Discussion
Patients who achieved cEVR have the best chance of achieving SVR [19], [20]. In our study, the cEVR rates were 73.5% and 78.1% in patients treated with IFNα-2b/RBV and PegIFNα-2a/RBV, respectively. The results were better than others reported on the early pivotal clinical trials, in which only 50%–66% patients infected with HCV achieved cEVR [21]–[23]. The reasons for this disparity might arise from host IL-28B genetic variation (rs12979860 CC genotype) [24] and low body weight in Chinese population which were associated with interferon sensitivity and treatment-induced viral clearance.
A favorable treatment response includes a strong cellular immune response against HCV antigens [25], [26]. To seek the role of cellular immune response in chronic hepatitis C patients with antiviral treatment, we investigated the dynamic changes of peripheral Tregs, PD-1 expressing T-cells and TLR3 expressing CD14+ monocytes in the patients. In the present study, proportions of Tregs and PD-1 expressing CD4+ T-cells or CD8+ T-cells were significantly increased in the patients at baseline as compared with the controls, indicating that the impaired cellular immune function might contribute to chronic HCV infection. It was reported that HCV infection had a high propensity to develop persistent viremia and was associated with ineffective viral-specific CD4+ and CD8+ T-cells responses [27], [28]. The cause of T-cells failure might relate to up-regulation of CD4+CD25+FoxP3+ Tregs [6] and PD-1 expressions [11], [13], [29]–[32] which inhibited HCV-specific CD4+ and CD8+ T-cells function.
Feld et al. [33] has suggested that the immune-modulatory activity of interferon and ribavirin therapy may be associated with enhancing T effector cells response to HCV, thus, the impaired cellular immunity by persistent HCV infection might be partially restored by interferon and ribavirin administration. In our study, there was a significant decrease of Tregs and PD-1 expressing CD8+ T-cells in chronic hepatitis C patients at 12 weeks after treatment compared with their baseline levels, indicating that IFN/RBV treatment could restore HCV-specific T-cells response by reducing circulating CD4+CD25+FoxP3+ Tregs and PD-1 expressing CD8+ T-cells. Furthermore, the decrease proportions of Tregs and PD-1 expressing CD4+ T-cells or CD8+ T-cells were more obvious in cEVR patients than those in non-cEVR cases. According to Thimme et al. [34], [35], T cell exhaustion contributed to the failure of about half of HCV-specific CD8+ T cell responses and the antiviral efficacy of HCV-specific CD8+ T cells was linked to surface expression of PD-1. Other studies had also reported that PD-1 was up-regulated on total CD4+ and CD8+ T cells in patients with chronic infection compared with normal subjects, and antiviral therapy that led to sustained elimination of circulating HCV RNA was associated with down-regulation of PD-1 on a wide range of cells [36], [37]. Besides PD-1 modulation, activation of Tregs also involved in impairment of HCV-specific T effector cells. Langhans’s study proposed that antiviral therapy is likely to shift the functional balance in the immune system between Tregs and T effector cells towards more efficacious effector responses in chronic hepatitis C patients. Our finding was in accordance with Langhans report [38], which indicated that interferon combined with ribavirin therapy could enhance proliferation of T effector cells as well as inhibit functions of Tregs, thus, reverses Treg-mediated suppression of T effector cells in chronic hepatitis C.
Treatment with IFNα-2b/RBV or PegIFNα-2a/RBV for 12 weeks, the frequencies of circulating Tregs and PD-1 expressing CD4+ in two groups or PD-1 expressing CD8+ T-cells in IFNα-2b/RBV group in patients who achieved cEVR were significantly lower than those in patients without cEVR. For PegIFNα-2a/RBV treated group, the frequencies of PD-1 expressing CD8+ was also lower in cEVR patients, but the P value was higher than 0.0167, perhaps on account of small sample size. Therefore, we speculated that Tregs and PD-1 could inhibit the responder cells population and function, which correlated with the risk of developing non-response. In contrast, patients who showed relatively abrogated capacity of Tregs and PD-1 might achieve cEVR and recover from HCV infection. This demonstrated that the suppression of Tregs and PD-1 might correlate with cEVR as it could generate an effective immune response and which provide a possible therapeutic target for immune modulation. However, whether the decrease in the frequency of Tregs and PD-1 expressing CD4+ or CD8+ T-cells were the necessary causes of cEVR warranted further investigation. No significant differences of the Tregs and PD-1 expressing CD4+ T-cells or CD8+ T-cells were found between IFNα-2b/RBV and PegIFNα-2a/RBV treated groups at any parallel time either from cEVR or non-cEVR, indicating that the immunomodulatory effects of IFNα-2b and PegIFNα-2a were comparable.
Activation of TLRs can induce both innate and adaptive immunity [39]. TLR3 signaling is induced by double-stranded (ds) RNA, a molecular signature of viruses, and is mediated by the TIR domain-containing adaptor-inducing IFN-β (TRIF) adaptor molecule. Thus, TLR3 plays an important role in the host response to viral infections [40]. The innate immune response activated through recognition of viral PAMPs by TLR3 leads to IFN-β induction, which in turn increases the interferon stimulated genes (ISGs) expression. Thus far, TLR3 expression in peripheral blood has not been well analyzed in chronic hepatitis C patients under antiviral treatment. Monocytes in peripheral blood were identified as the cells responding to TLRs stimulation [41]. In present study, we found that the level of TLR3 expressing CD14+ monocytes was elevated in chronic hepatitis C patients and further increased at 12 weeks, but returned to baseline level at 24 weeks after treatment with IFNα-2b/RBV or PegIFNα-2a/RBV. This change was more significant in cEVR patients than that in non-cEVR ones. This suggested that the anti-HCV treatment could increase TLR3 expressing CD14+ monocytes to enhance antiviral activity at early stage of treatment and restore the cell number and function to baseline level as HCV was cleared. An important finding coming from our TLR3 analysis was that lower peripheral TLR3 expressing CD14+ monocytes at baseline was an independent predictor for cEVR. In keeping with our findings, Hashad et al. [22] and Yuki et al. [23] found that pretreatment up-regulation of hepatic TLR3 expression was a predictive factor for non-respond. HCV infection could activate monocytes via TLRs pathway and elevate the expression of TLR3 as our study found, but pre-existing monocytes activation was a factor mediating reduced responses to TLR3 stimulation [42]. Thus, infection of monocytes by HCV may account for a defective response to HCV infection. Furthermore, the endogenous IFN system activation in the liver before treatment not only was ineffective in HCV clearance but also hampered further response to exogenous IFN plus RBV [37]. These reasons might explain why the level of TLR3 expressing CD14+ monocytes was lower in cEVR patients than that in non-cEVR ones, but further and expanded investigations were needed to clarify the underlying mechanisms. Therefore, the baseline level of peripheral TLR3 expressing CD14+ monocytes might serve as a predictor of response to antiviral therapy and have a substantial impact on treatment decision-making.
Conclusions
In summary, the present study suggested that low peripheral TLR3 expressing CD14+ monocytes at baseline was a novel predictor for early virological response of antiviral therapy in chronic HCV-infected patients. The patients treated with interferon plus ribavirin could achieve completely early virological response through the modulation of peripheral CD4+CD25+FoxP3+ regulatory T-cells, PD-1 expressing CD4+ or CD8+ T-cells and TLR3 expressing CD14+ monocytes.
Supporting Information
Checklist S1.
CONSORT 2010 checklist information to report the randomized parallel-group study. The study process, reported sections and topics, checklist item numbers, content and described sections in this manuscript were described.
https://doi.org/10.1371/journal.pone.0093620.s001
(DOC)
Protocol S1.
Study protocol in English. Study design and exclusion criteria for this study was presented in English in this protocol.
https://doi.org/10.1371/journal.pone.0093620.s002
(DOC)
Protocol S2.
Study protocol in Chinese. Study design and exclusion criteria for this study was presented in Chinese in this protocol.
https://doi.org/10.1371/journal.pone.0093620.s003
(DOC)
Acknowledgments
We are grateful to all subjects who generously provided blood samples for this study. A special thanks to Prof. Qing-bao Tian, Ms. Ying-jun Bei and Mrs. Xue-min Niu for their precious help in the statistic analysis of this manuscript.
Author Contributions
Conceived and designed the experiments: YN HZ DS. Performed the experiments: SS HH LK YZ SZ RW. Analyzed the data: YN HZ DS. Wrote the paper: SS YN JY.
References
- 1. Hadigan C, Kottilil S (2011) Hepatitis C virus infection and co-infection with human immunodeficiency virus: challenges and advancements in management. JAMA 306: 294–301.
- 2. Munir S, Saleem S, Idrees M, Tariq A, Butt S, et al. (2010) Hepatitis C treatment: current and future perspectives. Virol J 7: 296.
- 3. Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5: 558–567.
- 4. Marukian S, Jones CT, Andrus L, Evans MJ, Ritola KD, et al. (2008) Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology 48: 1843–1850.
- 5. Shiina M, Rehermann B (2008) Cell culture-produced hepatitis C virus impairs plasma cytoid dendritic cell function. Hepatology 47: 385–395.
- 6. Zheng Y, Rudensky AY (2007) Foxp3 in control of the regulatory T cell lineage. Nat Immunol 8: 457–462.
- 7. Speletas M, Argentou N, Germanidis G, Vasiliadis T, Mantzoukis K, et al. (2011) Foxp3 expression in liver correlates with the degree but not the cause of inflammation. Mediators Inflamm 827565: 1–9.
- 8. Tseng KC, Ho YC, Hsieh YH, Lai NS, Wen ZH, et al. (2012) Elevated frequency and function of regulatory T cells in patients with active chronic hepatitis C. J Gastroenterol. 47: 823–833.
- 9. Sarikonda G, von Herrath MG (2011) Immunosuppressive mechanisms during viral infectious diseases. Methods Mol Biol 677: 431–447.
- 10. Nakamoto N, Cho H, Shaked A, Olthoff K, Valiga ME, et al. (2009) Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog 5: e1000313.
- 11. Nakamoto N, Kaplan DE, Coleclough J, Li Y, Valiga ME, et al. (2008) Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology 134: 1927–1937.
- 12. Urbani S, Amadei B, Tola D, Pedrazzi G, Sacchelli L, et al. (2008) Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment. J Hepatol 48: 548–558.
- 13. Missale G, Pilli M, Zerbini A, Penna A, Ravanetti L, et al. (2012) Lack of full CD8 functional restoration after antiviral treatment for acute and chronic hepatitis C virus infection. Gut 61: 1076–1084.
- 14. Pasare C, Medzhitov R (2003) Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299: 1033–1036.
- 15. Hackl D, Loschko J, Sparwasser T, Reindl W, Krug AB (2011) Activation of dendritic cells via TLR7 reduces Foxp3 expression and suppressive function in induced Tregs. Eur J Immunol 41: 1334–1343.
- 16. Thomas A, Laxton C, Rodman J, Myangar N, Horscroft N, et al. (2007) Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection. Antimicrob Agents Chemother 51: 2969–2978.
- 17. Gao YT, Chen RY, Song WQ, Chen CB, Qi ZL, et al. (2004) Prepare and clinical application of HCV genotyping oligochip. Chin J Lab Med 27: 690–693.
- 18. Ghany MG, Nelson DR, Strader DB, Thomas DL (2011) Seeff LB; American Association for Study of Liver Diseases (2011) An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54: 1433–1444.
- 19. Chung HJ, Lee JW, Kim YS, Lee JI (2013) Prediction of sustained virologic response based on week 4 and week 12 response in hepatitis C virus genotype 1 patients treated with peginterferon and ribavirin: assessment in a favorable IL28B allele-prevalent area. Intervirology 56: 178–183.
- 20. Huang CF, Yang JF, Huang JF, Dai CY, Chiu CF, et al. (2010) Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response. J Gastroenterol Hepatol 25: 758–765.
- 21. Rodriguez-Torres M, Sulkowski MS, Chung RT, Hamzeh FM, Jensen DM (2010) Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population. J Viral Hepat 17: 139–147.
- 22. Hashad DI, Salem PE, Abdallah DM (2011) Toll like receptor 3 expression as a novel predictor of response to treatment in chronic hepatitis C virus patients. Scand J Clin Lab Invest 71: 641–646.
- 23. Yuki N, Matsumoto S, Kato M, Yamaguchi T (2010) Hepatic Toll-Like Receptor 3 expression in chronic hepatitis C genotype 1 correlates with treatment response to peginterferon plus ribavirin. J Viral Hepat 17: 130–138.
- 24. Liao XW, Ling Y, Li XH, Han Y, Zhang SY, et al. (2011) Association of genetic variation in IL28B with hepatitis C treatment-induced viral clearance in the Chinese Han population. Antivir Ther 16: 141–147.
- 25. Kamal SM, Fehr J, Roesler B, Peters T, Rasenack JW (2002) Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology. 123: 1070–1083.
- 26. Fitzmaurice K, Klenerman P (2008) Cellular immunity and acute hepatitis C infection. Curr Pharm Des 14: 1666–1677.
- 27. Bowen DG, Walker CM (2005) Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436: 946–952.
- 28. Frebel H, Richter K, Oxenius A (2010) How chronic viral infections impact on antigen-specific T-cell responses. Eur J Immunol 40: 654–663.
- 29. Yao S, Wang S, Zhu Y, Luo L, Zhu G, et al. (2009) PD-1 on dendritic cells impedes innate immunity against bacterial infection. Blood 113: 5811–5818.
- 30. Golden-Mason L, Palmer B, Klarquist J, Mengshol JA, Castelblanco N, et al. (2007) Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J Virol 81: 9249–9258.
- 31. Rutebemberwa A, Ray SC, Astemborski J, Levine J, Liu L, et al. (2008) High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection. J Immunol 181: 8215–8225.
- 32. Shen T, Zheng J, Liang H, Xu C, Chen X, et al. (2011) Characteristics and PD-1 expression of peripheral CD4+CD127l°CD25hiFoxP3+ Treg cells in chronic HCV infected-patients. Virol J 8: 279.
- 33. Feld JJ, Hoofnagle JH (2005) Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 436: 967–972.
- 34. Bengsch B, Seigel B, Ruhl M, Timm J, Kuntz M, et al. (2010) Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog 6: e1000947.
- 35. Seigel B, Bengsch B, Lohmann V, Bartenschlager R, Blum HE, et al. (2013) Factors that determine the antiviral efficacy of HCV-specific CD8(+) T cells ex vivo. Gastroenterology 144: 426–436.
- 36. Raziorrouh B, Ulsenheimer A, Schraut W, Heeg M, Kurktschiev P, et al. (2011) Inhibitory molecules that regulate expansion and restoration of HCV-specific CD4+ T cells in patients with chronic infection. Gastroenterology 141: 1422–1431.
- 37. Golden-Mason L, Klarquist J, Wahed AS, Rosen HR (2008) Cutting edge: programmed death-1 expression is increased on immunocytes in chronic hepatitis C virus and predicts failure of response to antiviral therapy: race-dependent differences. J Immunol 180: 3637–3641.
- 38. Langhans B, Nischalke HD, Arndt S, Braunschweiger I, Nattermann J, et al. (2012) Ribavirin exerts differential effects on functions of Cd4+ Th1, Th2, and regulatory T cell clones in hepatitis C. PLoS One. 7: e42094.
- 39. Gay NJ, Gangloff M (2007) Structure and function of Toll receptors and their ligands. Annu Rev Biochem 76: 141–165.
- 40. Schroder M, Bowie AG (2005) TLR3 in antiviral immunity: key player or bystander? Trends Immunol 26: 462–468.
- 41. Villacres MC, Literat O, DeGiacomo M, Du W, Frederick T, et al. (2008) Defective response to Toll-like receptor 3 and 4 ligands by activated monocytes in chronic hepatitis C virus infection. J Viral Hepat 15: 137–144.
- 42. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, et al. (2008) Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA. 105: 7034–7039.